G Estevez, L <br/><br/>
Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study.  [electronic resource] 

 -  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico  Jan 2009 
 - 54-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1699-048X 
<br/><br/><label>Standard No.: </label>10.1007/s12094-009-0311-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antigens, Neoplasm--biosynthesis<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--drug therapy<br/>Cyclophosphamide--administration & dosage<br/>DNA Topoisomerases, Type II--biosynthesis<br/>DNA-Binding Proteins--biosynthesis<br/>Docetaxel<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Immunohistochemistry<br/>Inhibitor of Apoptosis Proteins<br/>Microtubule-Associated Proteins--biosynthesis<br/>Middle Aged<br/>Neoadjuvant Therapy--methods<br/>Neoplasm Staging<br/>Proliferating Cell Nuclear Antigen--biosynthesis<br/>Survivin<br/>Taxoids--administration & dosage